Computer-Aided Drug Design Across Breast Cancer Subtypes: Methods, Applications and Translational Outlook
International Journal of Molecular Sciences · 05.11.2025 · 26 (21) · 10744
DOI: 10.3390/ijms262110744 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift International Journal of Molecular Sciences, online erschienen am 05.11.2025. Verfasst von Wei Tian und 4 weiteren Autor:innen. Beteiligte Einrichtung: School of Life Science and Technology, Wuhan Polytechnic University, Wuhan 430023, China. Hauptthemen laut MEDLINE: Breast Neoplasms, Drug Design, Computer-Aided Design, Antineoplastic Agents. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 144 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: EDUCATIONAL COMMISSION OF HUBEI PROVINCE OF CHINA, RESEARCH PROJECT OF WUHAN POLYTECHNIC UNIVERSITY, SCIENCE AND TECHNOLOGY TALENT SERVING ENTERPRISES PROJECT OF HUBEI PROVINCIAL DEPARTMENT OF SCIENCE AND TECHNOLOGY.
Abstract (Originalsprache)
Breast cancer is a heterogeneous malignancy with distinct molecular subtypes that complicate the development of effective therapies. Traditional drug discovery methods are often constrained by high cost and long development timelines, underscoring the need for more efficient, subtype-aware approaches. Computer-aided drug design (CADD) has emerged as a valuable strategy to accelerate therapeutic discovery and improve lead optimization. This review synthesizes advances from a subtype-centric perspective and outlines the application of CADD techniques, including molecular docking, virtual screening (VS), pharmacophore modeling, and molecular dynamics (MD) simulations, to identify potential targets and inhibitors in receptor-positive (Luminal), HER2-positive (HER2+), and triple-negative breast cancer (TNBC). In addition to traditional pipelines, we highlight artificial intelligence (AI)-enabled methods and a hybrid workflow in which learning-based models rapidly triage chemical space while physics-based simulations provide mechanistic validation. These approaches have facilitated the discovery of subtype-specific compounds and enabled the refinement of candidate drugs to enhance efficacy and reduce toxicity. Despite these advances, critical challenges remain, particularly tumor heterogeneity, drug resistance, and the need to rigorously validate computational predictions through experimental studies. Future progress is expected to be driven by the integration of AI, machine learning (ML), multi-omics data, and digital pathology, which may enable the design of more precise, subtype-informed, and personalized therapeutic strategies for breast cancer.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- School of Life Science and Technology, Wuhan Polytechnic University, Wuhan 430023, China.
ORCID-Profile: Wei Tian
Förderung
- EDUCATIONAL COMMISSION OF HUBEI PROVINCE OF CHINA
- RESEARCH PROJECT OF WUHAN POLYTECHNIC UNIVERSITY
- SCIENCE AND TECHNOLOGY TALENT SERVING ENTERPRISES PROJECT OF HUBEI PROVINCIAL DEPARTMENT OF SCIENCE AND TECHNOLOGY
- Hubei Provincial Department of Education
Zitieren
APA
Tian, W., Hu, Y., Gao, X., Yang, J., & Jiang, W. (2025). Computer-Aided Drug Design Across Breast Cancer Subtypes: Methods, Applications and Translational Outlook. International Journal of Molecular Sciences, 26(21), 10744. https://doi.org/10.3390/ijms262110744
Vancouver
Tian W, Hu Y, Gao X, Yang J, Jiang W. Computer-Aided Drug Design Across Breast Cancer Subtypes: Methods, Applications and Translational Outlook. International Journal of Molecular Sciences. 2025;26(21):10744. doi:10.3390/ijms262110744
BibTeX
@article{Tian2025,
author = {Tian, Wei and Hu, Ying and Gao, Xinyu and Yang, Jinghui and Jiang, Wei},
title = {Computer-Aided Drug Design Across Breast Cancer Subtypes: Methods, Applications and Translational Outlook},
journal = {International Journal of Molecular Sciences},
year = {2025},
volume = {26},
number = {21},
pages = {10744},
doi = {10.3390/ijms262110744}
}
EUVIMED